Brought to you by 
Novartis licenses Array BioPharma's MEK inhibitors; terminated
04 Jun 2021
Executive Summary
Novartis Pharmaceuticals Corp. has licensed exclusive global rights to several of Array BioPharma Inc.'s (cancer, inflammation, and metabolic therapeutics) small-molecule MEK inhibitors, including Phase I ARRY162 for cancer and its back-up compound, ARRY300.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis licenses Array BioPharma's MEK inhibitors; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice